Measurement of trimethylamine-N-oxide by stable isotope dilution liquid chromatography tandem mass spectrometry

Zeneng Wang a,*, Bruce S. Levison a, Jennie E. Hazen a, Lillian Donahue a, Xin-Min Li a, Stanley L. Hazen a,b

aDepartment of Cellular & Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
bDepartment of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH 44195, USA

A R T I C L E   I N F O

Article history:
Received 22 November 2013
Received in revised form 23 March 2014
Accepted 24 March 2014
Available online 1 April 2014

Keywords:
Trimethylamine-N-oxide
Cardiovascular disease
Mass spectrometry

A B S T R A C T

Trimethylamine-N-oxide (TMAO) levels in blood predict future risk for major adverse cardiac events including myocardial infarction, stroke, and death. Thus, the rapid determination of circulating TMAO concentration is of clinical interest. Here we report a method to measure TMAO in biological matrices by stable isotope dilution liquid chromatography tandem mass spectrometry (LC/MS/MS) with lower and upper limits of quantification of 0.05 and >200 M, respectively. Spike and recovery studies demonstrate an accuracy at low (0.5 μM), mid (5 μM), and high (100 μM) levels of 98.2, 97.3, and 101.6%, respectively. Additional assay performance metrics include intraday and interday coefficients of variance of <6.4 and <9.9%, respectively, across the range of TMAO levels. Stability studies reveal that TMAO in plasma is stable both during storage at −80 °C for 5 years and to multiple freeze thaw cycles. Fasting plasma normal range studies among apparently healthy subjects (n = 349) show a range of 0.73–126 μM, median (interquartile range) levels of 3.45 (2.25–5.79) μM, and increasing values with age. The LC/MS/MS-based assay reported should be of value for further studies evaluating TMAO as a risk marker and for examining the effect of dietary, pharmacologic, and environmental factors on TMAO levels.

© 2014 Elsevier Inc. All rights reserved.
clinical diagnostic test has not yet been reported. In the present report we describe a rapid, sensitive and accurate approach for the quantification of TMAO in biological matrices using stable isotope dilution liquid chromatography with on-line electrospray ionization tandem mass spectrometry (LC/MS/MS).

Materials and methods

Reagents

Deuterated trimethylamine-N-oxide (d$_9$-TMAO) was purchased from Cambridge Isotope Laboratories (Cat. No. DLM-4779-1, Andover, MA). All other reagents were purchased from either Sigma-Aldrich (St. Louis, MO) or Fisher Scientific Chemicals (Pittsburg, PA) unless otherwise stated.

Research subjects

Samples and associated clinical data were collected from fasting subjects undergoing community health screens. All subjects gave written informed consent and the Institutional Review Board of the Cleveland Clinic approved all study protocols.

Sample processing

Samples (20 µl plasma or serum) were aliquoted to a 1.5 ml Eppendorf tube and mixed with 80 µl of 10 µM internal standard comprised of d$_9$-TMAO in methanol. Protein in the samples was precipitated by vortexing for 1 min and then the supernatant was recovered following centrifugation at 20,000 g at 4 °C for 10 min. In general, when analyzing TMAO levels, we run 3 different quality control (QC) samples with TMAO concentrations ranging between 0.25 and 20 µM in duplicate before each sample batch of less than 30 samples. TMAO concentrations from the batch were acceptable when the accuracy of the values determined from each QC sample were within 100 ± 10% of their expected values and the intrabatch CVs for the same QC samples were all less than 10%.

LC/MS/MS

Supernatants (10 µl) were analyzed by injection onto a silica column (4.6 × 250 mm, 5 µm Luna silica; Cat. No. 00G-4274-E0, Phenomenex, Torrance, CA) at a flow rate of 0.8 ml min$^{-1}$ using a 4 LC-20AD Shimadzu pump system, SIL-HTC autosampler, and dual column switching valve system (2 Rheodyne 6 port automated valves, Cat. No. MXP7900, IDEX Health & Science, Oak Harbor, WA) [10] interfaced with an API 4000 Q-TRAP mass spectrometer (AB SCIEX, Framingham, MA). A discontinuous gradient was generated to resolve the analytes by mixing solvent A (0.1% propanoic acid in water) with solvent B (0.1% acetic acid in methanol) at different ratios starting from 2% B linearly to 15% B over 10 min, then linearly to 100% B over 2.5 min, then hold for 3 min, and then back to 2% B. TMAO and d$_9$-TMAO were monitored using electrospray ionization in positive-ion mode with multiple reaction monitoring (MRM) of precursor and characteristic product-ion transitions of m/z 76 → 58 and 85 → 66 amu, respectively. The parameters for the ion monitoring were as follows: spray voltage, 4.5 kV; curtain gas, 15; GS1, 60; GS2, 50; CAD gas, medium; DP, 60; CE, 25.0 V for TMAO and 28.3 V for d$_9$-TMAO; CXP, 10; EP, 10. Nitrogen (99.95% purity) was used as the source and colliison gas. Various concentrations of nonisotopically labeled TMAO standard were spiked into control plasma to prepare the calibration curves for quantification of TMAO. The internal standard d$_9$-TMAO was used for quantification as well as to calculate recovery rate of TMAO (which was 99 ± 1% based on separate control studies).

Precision, accuracy, limit of quantitation, and linearity

Four replicates were performed on a single day to establish the intraday coefficient of variation (CV) for 6 different pooled plasma samples with different concentrations of TMAO. The interday CV was determined by assaying aliquots of these pooled samples daily over a span of more than 20 days. Carryover between injections was not observed. Accuracy is expressed as the ratio of the TMAO concentration measured to the TMAO concentration added to a plasma sample that was dialyzed against 1000 vol of 0.89% NaCl for 3 times. The lower limit of detection (LLOD) was defined as the lowest concentration of TMAO spiked into the dialyzed plasma on-column generating a signal-to-noise ratio of 3. The lower limit of quantification (LLOQ) was determined by reducing the concentration of standard solution gradually to the dialyzed plasma and is expressed as the lowest concentration yielding a signal-to-noise ratio of 10. No upper limit of quantification (ULOQ) was found, with linear responses noted in serially diluted samples spiked with increasing the concentration of standard solution as long as the diluted sample (concentration, peak area ratio of TMAO/d$_9$-TMAO) was still situated on the standard curve. To determine assay linearity, a standard curve over the 0.01–200 µM concentration range was checked for linearity by linear regression fit. The linear range was defined as the region of the standard curve where the difference between calculated TMAO concentration and standard TMAO concentration was less than 15%.

Results

Optimization of parameters for mass spectrometric assay of TMAO and d$_9$-TMAO

In order to determine the TMAO concentration in human blood, we first optimized the parameters for TMAO and its isotope labeled internal standard, d$_9$-TMAO, by direct infusion of these two standards. Shown in Fig. 1A and B are the collision-induced dissociation (CID) mass spectra of TMAO and d$_9$-TMAO, which are fragmented with collision energy of 25 eV. The product ions are 58 and 59 amu for TMAO, which are due to loss of water and hydroxyl group, respectively, as are the product ions for d$_9$-TMAO at 66

Fig. 1. Collision-induced dissociation (CID) mass spectra of trimethylamine-N-oxide (TMAO, Panel A) and trimethylamine-N-oxide-d$_9$ (d$_9$-TMAO, Panel B). Proposed pathways for formation of the fragment ions are also shown.
and 68 amu. The intensity ratios of the two product ions are different between TMAO and d$_7$-TMAO due to the difference in bond energy among C and H and C and D (deuterium). We therefore quantified TMAO and d$_7$-TMAO in the MRM mode using the precursor to product transitions 76 → 58 and 85 → 66 amu, respectively. Among all the instrument parameters, collision energy (CE) was the most critical one.

**Validation of the LC/MS/MS assay for TMAO in human plasma**

Fig. 2A and B shows the selected ion extraction LC chromatograms of TMAO and d$_7$-TMAO standards (in buffer) in positive MRM mode. Fig. 2C and D shows the LC chromatograms extracted in plasma after spiking with d$_7$-TMAO internal standard in methanol followed by precipitation to remove protein. TMAO and d$_7$-TMAO have nearly the same retention times in the LC chromatograms. The data acquisition window is 6 min, and began after an initial 4.5 min of column eluent diversion to waste. To increase sample throughput, we routinely use 2 multiplexed binary pump HPLC system equipped with separate columns and automated column valve system [10], allowing for data acquisition only during a narrower time window from each column (Fig. 3). The current column and gradient presented are what we typically use, and allows for an ~11 min per sample run time, while also allowing multiple additional biogenic amines and amino acids to simultaneously be quantified in multiple reaction monitoring mode [11]. If only quantifying TMAO, we increase throughput per sample to ~5 min by using a shorter column and gradient (not shown). Following data acquisition, peak areas of TMAO and d$_7$-TMAO were determined using Analyst 1.4.1 software and the peak area ratio is used to quantify TMAO. Using a series of concentrations of TMAO standard mixed with a fixed amount of d$_7$-TMAO internal standard spiked or nonspiked into plasma, we prepared calibration curves, which are shown in Fig. 4A and B. The Y axis intercept in Fig. 4B (nondialyzed plasma) corresponds to the endogenous TMAO concentration, which can be calculated as intercept/slope. The slopes of the two standard curves showed a difference of <3.2%. By spiking a series of concentrations of TMAO standards into 8 different plasma samples to prepare the standard curves, we got a slope (mean ± SD) of 0.0156 ± 0.0003, suggesting that using different spiked plasmas to generate the calibration curves for TMAO gives an error of <2.0%. These data also indicate that in either EDTA plasma (shown) or serum (not shown) the matrix effect for quantifying TMAO by the method described is negligible.

**Assay performance metrics**

To examine assay precision, TMAO concentration was measured in 6 different pooled plasma samples with different TMAO levels, on multiple different days. Table 1 shows the intraday and interday CV% for TMAO observed, all of which were less than 6.4 and 9.9, respectively, regardless of the TMAO level. The pooled plasma TMAO concentrations used were as low as 0.82 μM and as high as 102.4 μM, whose range embraces 99% subjects (see below). Additional assay performance metrics including accuracy across a span of different concentrations of TMAO (all ≥95%), LLOD, LLOQ, and ULOQ are given in Table 2. The LC chromatogram of the TMAO standard spiked into the dialyzed plasma with a concentration at LLOQ is shown in Fig. 5A. Fig. 5B shows the LC chromatogram of TMAO in human plasma with the lowest concentration (0.06 μM) we have ever measured among more than 4000 subjects. The assay was found to be linear across the range examined (0.1–200 μM). Dilution of plasma samples containing higher TMAO levels (the highest endogenous level yet observed is 4.8 mM) with water gave an accuracy of greater than 98%.

**Normal range of fasting plasma TMAO in healthy subjects**

To assess the normal range of fasting (>12 h) TMAO levels, apparently healthy subjects (n = 349) undergoing routine health screens in the community were examined. Fig. 6A shows the plasma TMAO concentration distribution, and Table 3 describes the clinical and laboratory characteristics observed. Within the healthy cohort, 5% demonstrated mild hypertension and 5% of them were current smokers. The median (interquartile range) levels of TMAO noted was 3.45 (2.25–5.79) μM. Male and female TMAO levels showed no significant differences, though TMAO levels did show increases with age (Fig. 6B).

**Stability studies**

In order to investigate the stability of TMAO in plasma during storage, we measured TMAO concentrations in a collection of samples in which initial levels were determined using stable isotope dilution LC/MS/MS analyses over 5 years ago, and for which samples had been maintained at ~80 °C. Fig. 7 shows results of the comparison in TMAO levels between the two time points, and
The different levels of TMAO reveal a high correlation ($r^2 = 0.98$) with slope and $Y$ intercept very close to 1 and 0, respectively, indicating that TMAO is stable during storage at $-80\,^\circ C$. Separate studies examining the stability of TMAO through multiple freeze thaw cycles showed that TMAO levels do not significantly change, with intercycle CV% less than 10 (Table 4).

**Discussion**

Herein we present an LC/MS/MS method for the measurement of TMAO levels in biological matrices with high accuracy, precision, and throughput that is amenable to the demands of clinical diagnostic practice. Using multiplexed HPLC with column switching, shorter column, and further optimization of the column gradients, we have adapted the stable isotope dilution LC/MS/MS assay described to permit a between sample acquisition time of 5 min (averaged) without affecting assay results or the column longevity. With a LLOQ of 0.05 $\mu M$, which is well below the lowest TMAO level observed among the $>300$ healthy volunteers examined, a highly accurate TMAO level was able to be determined in every subject examined. The linear relationship observed across the large dynamic range explored in the standard curve (up to 200 $\mu M$) is suitable for the majority of samples in human population studies. In our experience, which cumulatively includes analyses of over 4000 individuals (both healthy subjects and cardiovascular disease patients), the lowest plasma TMAO level observed thus far has been 0.06 $\mu M$ (Fig. 5B), which is higher than the LLOQ, and the maximum level observed has been 4.8 mM. In the present studies, which report for the first time the normal range of fasting plasma TMAO levels among apparently healthy adult subjects, plasma TMAO levels at the 0.5 percentile level cutoff were 0.78 $\mu M$ and at the 99.5 percentile cutoff were 46.0 $\mu M$. Previously, we mea-
Table 3
Clinical and laboratory characteristics of healthy controls.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All participants (n = 349)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age-years</td>
<td>54 ± 16</td>
</tr>
<tr>
<td>Male sex-%</td>
<td>33</td>
</tr>
<tr>
<td>Median body-mass index (interquartile range)</td>
<td>25 (23–29)</td>
</tr>
<tr>
<td>Hypertension-%</td>
<td>5</td>
</tr>
<tr>
<td>Current or former smoker-%</td>
<td>5</td>
</tr>
<tr>
<td>Median cholesterol (interquartile range)–mg/dl</td>
<td>117 (95–142)</td>
</tr>
<tr>
<td>Low-density lipoprotein</td>
<td></td>
</tr>
<tr>
<td>High-density lipoprotein</td>
<td>53 (45–64)</td>
</tr>
<tr>
<td>Median triglycerides (interquartile range)–mg/dl</td>
<td>102 (73–154)</td>
</tr>
<tr>
<td>Lipoprotein (interquartile range)–mg/dl</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>58 (67–98)</td>
</tr>
<tr>
<td>A1</td>
<td>150 (132–171)</td>
</tr>
<tr>
<td>A2</td>
<td>38 (34–43)</td>
</tr>
<tr>
<td>Median TMAO (interquartile range)–μM</td>
<td>3.4 (2.3–5.8)</td>
</tr>
</tbody>
</table>

All subjects gave written informed consent and the Institutional Review Board of the Cleveland Clinic approved all study protocols. Fasting lipid profiles were measured on the Abbott ARCHITECT platform (Abbott Diagnostics, Abbott Park, IL).

Fig. 6. (A) Distribution of TMAO concentrations in healthy volunteers (n = 349). Lower bar gives the concentrations of TMAO at each percentile. (B) Box whisker plot showing distribution of the TMAO concentration with respect to age and gender in the former population (n = 349). The population was segregated by age and gender as shown on the lower axis. Horizontal middle of box = TMAO concentration at median value, top of box at 75th percentile, bottom of box at 25th percentile, top of whisker at 97.5 percentile, and bottom of whisker at 2.5 percentile in the specified population.

Fig. 7. The stability of TMAO in frozen plasma samples after long-term storage (5 years at −80 °C). The same set of 124 human plasma samples (randomly selected from GenBank, a large (n = 10,000) and well-characterized tissue repository with longitudinal data from sequential consenting subjects undergoing elective diagnostic left heart catheterization) was measured in December 2007 and in December 2012 by LC/MS/MS. The plasma samples were collected between November 5, 2001, and April 5, 2005, and kept frozen at −80 °C until assay. All plasma samples were defrosted at least 2 times.

Table 4
Evaluation of three QC plasma TMAO concentrations which were subjected to 5 freeze and thaw cycles.

<table>
<thead>
<tr>
<th>QC Plasma</th>
<th>Cycle 1</th>
<th>Cycle 2</th>
<th>Cycle 3</th>
<th>Cycle 4</th>
<th>Cycle 5</th>
<th>CV%</th>
<th>Intercycle</th>
<th>Intracycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma TMAO (μM)</td>
<td>1.61</td>
<td>1.77</td>
<td>1.78</td>
<td>1.75</td>
<td>1.71</td>
<td>4.1</td>
<td>2.6</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.68</td>
<td>1.77</td>
<td>1.71</td>
<td>1.74</td>
<td>1.80</td>
<td>8.8</td>
<td>3.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.47</td>
<td>2.71</td>
<td>2.99</td>
<td>2.58</td>
<td>2.66</td>
<td>2.38</td>
<td>2.58</td>
<td></td>
</tr>
<tr>
<td></td>
<td>15.2</td>
<td>16.2</td>
<td>16.3</td>
<td>15.1</td>
<td>15.3</td>
<td>2.9</td>
<td>3.4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>14.9</td>
<td>15.4</td>
<td>15.2</td>
<td>15.9</td>
<td>15.3</td>
<td>14.9</td>
<td>15.4</td>
<td></td>
</tr>
</tbody>
</table>

Plasma were frozen at −80 °C in a dry ice box and thawed to room temperature. The same vial of plasma was subjected to five freeze and thaw cycles. TMAO in each sample at each cycle was measured in duplicate.

Plasma TMAO levels in a large patient population that consisted of 4007 sequential subjects with largely preserved renal function undergoing elective diagnostic cardiac evaluations [3]. In those studies, we examined the relationship between TMAO levels and risk for both prevalent cardiovascular disease and incident risk for myocardial infarction, stroke, or death within the 3 years following sample collection and observed a hazard ratio for highest vs lowest TMAO quartile of 2.54-fold (95% confidence interval, 1.96 to 3.28; P < 0.0001) [3]. Of note, the extremes of TMAO levels observed within this cardiology clinic cohort are similar (i.e., the 0.5 percentile was 0.63 μM and the 99.5 percentile was 77.2 μM) to those observed in the healthy volunteers reported in the present study. Therefore, most of the plasma TMAO levels that will likely be observed in subjects will be situated within the linearity range, 0.1–200 μM, developed for the present assay. The results of the stability studies shown for TMAO in plasma during storage at −80 °C indicate that analyses of TMAO in archival specimens of long duration will be a reliable indicator of the TMAO levels. Although TMAO can work as electron acceptor in bacteria [12,13], its oxidative potential is very limited. Thus, it is perhaps not surprising that the present study demonstrates negligible impact of multiple freeze–thaw cycles on TMAO levels, attesting to the stability of this analyte in sterile complex biological matrices. Thus, TMAO does not readily undergo spontaneous degradation, and alternatively, trimethylamine-containing precursors such as cholene, phosphatidylcholine, and carnitine do not readily contribute to the formation of TMAO during storage. The accuracy, precision, and high-throughput nature of the presently described LC/MS/MS assay should greatly facilitate the exploration of the clinical utility of this unique and interesting biomarker of human health and disease.
Competing financial interests

Drs. Hazen, Wang, and Levison report being listed as co-inventor on pending patents held by the Cleveland Clinic relating to cardiovascular diagnostics and therapeutics. Dr. Hazen reports having been paid as a consultant for the following companies: AstraZeneca Development LP, BG Medicine, Inc., Cleveland Heart Lab, Esperion, Lilly, Liposcience, Inc., Merck & Co., Inc., Pfizer, Inc., and Proctor & Gamble, and Takeda. Dr. Hazen reports receiving research funds from Cleveland Heart Lab, Liposcience, Inc., Proctor & Gamble, and Takeda. Dr. Hazen reports having the right to receive royalty payments for inventions or discoveries related to cardiovascular diagnostics and therapeutics for the companies shown below: Cleveland Heart Lab, Frantz Biomarkers, LLC, Liposcience, Inc. Drs. Levison and Wang report having the right to receive royalty payments for inventions or discoveries related to cardiovascular diagnostics from Liposcience, Inc., and Proctor & Gamble.

Acknowledgments

S.L.H. is supported by United States National Institutes of Health (NIH) and Office of Dietary Supplement Grant R01 HL103866, and NIH Grant P20 HL113452. S.L.H. is also partially supported by a gift from the Leonard Krieger Fund. Z.W. is partially supported by an American Heart Association Scientist Development Grant (12SDG12050473). Mass spectrometry instrumentation used is housed in a facility partially supported by a Center of Innovation Award from AB SCIEX.

References